Returning guest, Derek Wallace, MBBS, Vice President and Global Dengue Program Head at Takeda, discusses the approval of the company’s dengue vaccine, QDENGA ® (TAK-003), in Indonesia for those six years to 45 years of age. It is the only dengue vaccine approved in Indonesia that does not require pre-vaccination testing. The approval is based on the positive long-term results from the pivotal Phase 3 TIDES trial through 36 months follow-up. QDENGA is currently undergoing regulatory review in the European Union and other dengue-endemic countries outside the EU through the EU-M4all procedure with some decisions expected in Takeda’s FY22. Takeda also plans to file in the U.S. soon. More on the announcement here.   

Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, he leads the global program team in the development of Takeda’s dengue vaccine, QDENGA ® (TAK-003). Dr. Wallace joined Takeda in September 2013 as Global Program Medical Director.    Dr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, he held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Dr. Wallace served as clinical team leader for Sanofi’s dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women’s health.    Dr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.

Liked it? Take a second to support healthprofessionalradio on Patreon!